Gastrointestinal Pharmacology

Correct Answer

B — Polyethylene glycol 3350

Rationale

Polyethylene glycol 3350 is classified as an osmotic laxative. Bisacodyl and senna are stimulant laxatives that activate myenteric plexus neurons. Lubiprostone is a type-2 chloride channel activator.

Correct Answer

D — Methylnaltrexone

Rationale

Methylnaltrexone is classified as a peripherally acting mu-opioid receptor antagonist (PAMORA). Loperamide is a mu-opioid receptor agonist used as an antidiarrheal. Lubiprostone is a type-2 chloride channel activator. Linaclotide is a guanylate cyclase-C agonist.

Correct Answer

A — Type-2 chloride channel activator that drives chloride and water secretion into the intestinal lumen from epithelial cells

Rationale

Lubiprostone activates type-2 chloride channels (ClC-2) on the apical surface of intestinal epithelial cells. Channel activation drives chloride ions into the intestinal lumen, with water following osmotically, increasing luminal fluid content and accelerating transit. It has minimal systemic absorption, confining its activity to the intestinal lumen. Lubiprostone is approved for chronic idiopathic constipation, IBS with predominant constipation, and opioid-induced constipation. Its most common adverse effect is nausea, reduced by taking with food. Linaclotide and plecanatide are the guanylate cyclase-C agonists (option B), which share the secretory mechanism but act through a different receptor and second messenger cascade. The distinction between ClC-2 activation and GCC agonism is a testable detail at the second-year level.

Correct Answer

C — Loperamide

Rationale

Loperamide is classified as a mu-opioid receptor agonist. Bismuth subsalicylate is a bismuth salt with antimicrobial and anti-secretory properties. Alosetron is a serotonin 5-HT3 receptor antagonist. Eluxadoline is a mixed mu/delta/kappa opioid receptor agent.

Correct Answer

D — Minimally absorbed macrolide antibiotic that inhibits bacterial RNA polymerase; lower recurrence rates than vancomycin due to narrower spectrum preserving colonization resistance

Rationale

Fidaxomicin is a macrolide antibiotic with less than 1 percent systemic bioavailability, achieving high intraluminal concentrations against C. difficile while sparing systemic antibiotic effects. It inhibits bacterial RNA polymerase at a site distinct from rifamycins. Its key clinical advantage over oral vancomycin is a significantly lower recurrence rate — approximately 40 percent lower for non-hypervirulent strains — attributed to its narrow spectrum that spares the colonization-resistance organisms (particularly Bacteroides spp.) that vancomycin suppresses. The preserved microbiome provides competition that limits C. difficile regrowth after treatment. Option A describes oral vancomycin (glycopeptide, cell wall inhibition); option B describes bezlotoxumab; option C describes metronidazole, which is no longer first-line for any CDI severity category per current IDSA/SHEA guidelines.

Correct Answer

B — Linaclotide

Rationale

Linaclotide is classified as a guanylate cyclase-C agonist. Lubiprostone is a type-2 chloride channel activator. Polyethylene glycol 3350 is an osmotic laxative. Methylnaltrexone is a peripherally acting mu-opioid receptor antagonist.

Correct Answer

C — Opioids activate mu-opioid receptors throughout the enteric nervous system, producing a receptor-mediated motility disorder that osmotic and stimulant laxatives do not address at the receptor level

Rationale

Opioid-induced constipation arises from mu-opioid receptor activation in the enteric nervous system, which is present at the highest density of any extracentral site. This produces reduced propulsive motility, increased segmental non-propulsive contractions, reduced secretion, and increased anal sphincter tone — a coordinated receptor-mediated inhibition of GI function. Osmotic laxatives increase luminal water content and stimulant laxatives activate myenteric neurons, but neither approach blocks the upstream mu-opioid receptor drive that continuously suppresses propulsive activity. As long as opioid receptors in the gut wall remain activated, these downstream mechanisms are fighting against an active pharmacological brake. Peripherally acting mu-opioid receptor antagonists (methylnaltrexone, naloxegol, naldemedine) address the problem at its source by blocking the receptor that is causing the dysfunction.

Correct Answer

A — Inhibiting colonic motility in C. difficile infection traps toxin-producing organisms in the colon, promoting transmural inflammation and toxic megacolon

Rationale

The diarrhea of C. difficile infection serves a physiological function — it is the host's attempt to clear the toxin-producing organism and its toxins from the colon. Loperamide's mu-opioid receptor agonism in the myenteric plexus stops propulsive colonic motility, trapping C. difficile and its toxins (toxin A and toxin B) in prolonged contact with the colonic wall. Continued toxin exposure drives progressive mucosal and transmural injury, colonic dilation, and the potentially fatal complication of toxic megacolon — defined as non-obstructive colonic dilation exceeding 6 cm with systemic toxicity. The same contraindication applies to dysenteric presentations with bloody stool or high fever (invasive organisms require motility for clearance) and acute severe ulcerative colitis flares.

Correct Answer

B — Oral vancomycin has negligible systemic absorption; the oral dose transits the GI tract intact, achieving fecal concentrations exceeding 1000 mcg/mL that far exceed the MIC for C. difficile

Rationale

Vancomycin is a large glycopeptide with negligible oral bioavailability — essentially none is absorbed from the gastrointestinal tract under normal circumstances. The drug transits the bowel intact and reaches the colon at very high concentrations; stool concentrations of more than 1000 mcg/mL have been measured, far exceeding the minimum inhibitory concentration for C. difficile. This property transforms what would otherwise be a disadvantage (poor oral absorption) into the pharmacokinetic basis of its clinical utility in CDI: high luminal concentration is exactly what is needed to treat an intraluminal infection, while negligible systemic absorption avoids the nephrotoxicity and ototoxicity associated with intravenous vancomycin. Intravenous vancomycin does not work for CDI precisely because it does not penetrate the bowel lumen in therapeutic concentrations.

Correct Answer

D — Fidaxomicin's narrow spectrum spares colonization-resistance organisms that vancomycin suppresses; the preserved microbiome limits C. difficile regrowth after treatment ends

Rationale

The gut microbiome provides colonization resistance — competition from commensal organisms, particularly Bacteroides species and other anaerobes, that occupy ecological niches and limit C. difficile expansion. Oral vancomycin is a broad-spectrum agent against gram-positive flora that suppresses many of these colonization-resistance organisms alongside C. difficile. When vancomycin is stopped, C. difficile spores germinate in a microbiome-depleted environment with reduced competition, facilitating recurrence. Fidaxomicin has a substantially narrower spectrum that is highly active against C. difficile but spares most Bacteroides and other gram-negative anaerobes that provide colonization resistance. The preserved microbiome after fidaxomicin treatment limits the ecological opportunity for C. difficile regrowth, explaining the approximately 40 percent lower recurrence rate compared with vancomycin for non-hypervirulent strains.

Correct Answer

A — Ischemic colitis and severe constipation, including cases requiring hospitalization and surgery, reported after market approval

Rationale

Alosetron was withdrawn from the US market in 2000 — less than a year after its 1999 approval — due to post-marketing reports of ischemic colitis and severe constipation leading to hospitalizations, surgeries, and deaths. The 5-HT3 receptor antagonism that slows colonic transit and reduces urgency (the therapeutic effect) also reduces colonic blood flow in susceptible patients, causing ischemic injury. It was reintroduced in 2002 under a restricted REMS program permitting use only in women with severe IBS-D that has not responded to conventional therapies, only when prescribed by enrolled physicians, and with mandatory patient education to stop the drug immediately if constipation or rectal bleeding develops. Option B describes eluxadoline's sphincter of Oddi spasm risk in post-cholecystectomy patients — a different IBS-D drug with a different mechanism.

Correct Answer

C — Eluxadoline's mu-opioid receptor agonism at the sphincter of Oddi causes spasm; without the gallbladder's pressure-buffering reservoir, unopposed sphincter spasm produces acute pancreatitis

Rationale

Eluxadoline is a mixed opioid receptor modulator — mu-opioid agonist, kappa-opioid agonist, and delta-opioid antagonist — that reduces intestinal secretion and motility. The sphincter of Oddi contains mu-opioid receptors; mu-opioid agonism causes sphincter contraction and spasm. In patients with an intact gallbladder, the gallbladder serves as a pressure-buffering reservoir: when sphincter spasm temporarily obstructs bile and pancreatic juice outflow, pressure is accommodated by gallbladder expansion. After cholecystectomy, this reservoir is absent. Sphincter of Oddi spasm causes unrelieved biliary and pancreatic duct hypertension, which can rapidly produce acute pancreatitis. Post-cholecystectomy patients are therefore at substantially higher risk of eluxadoline-induced pancreatitis and must not receive the drug. This is an absolute contraindication, not a precaution.

Correct Answer

D — Human monoclonal antibody against C. difficile toxin B that prevents the cytotoxin from binding colonic epithelial cells, reducing recurrence risk without treating active infection

Rationale

Bezlotoxumab is a fully human monoclonal antibody that binds C. difficile toxin B — the primary cytotoxin responsible for colonic epithelial destruction in CDI — and prevents it from binding its receptor on colonic cells. A critical conceptual point: bezlotoxumab does not treat the active C. difficile infection itself. It has no direct antibacterial activity and does not affect the organism. It is given alongside the antibiotic (vancomycin or fidaxomicin) that treats the infection; bezlotoxumab's role is to neutralize circulating toxin B and reduce recurrence risk in high-risk patients (aged 65 or older, immunocompromised, prior CDI episodes). In clinical trials it reduced recurrence from approximately 26 percent to 17 percent. It carries a black box warning for heart failure exacerbation.

Correct Answer

B — TCAs' anticholinergic activity slows GI transit, which is therapeutically beneficial in IBS-D but worsens the already-slowed transit of IBS-C

Rationale

Low-dose TCAs reduce visceral pain through sodium channel blockade on sensory neurons and enhanced descending pain inhibition — mechanisms independent of their antidepressant effect and active across IBS subtypes. However, TCAs also block muscarinic receptors (anticholinergic activity), reducing intestinal cholinergic drive, slowing motility, and decreasing secretion. In IBS-D, this transit-slowing effect is directly therapeutic, reducing stool frequency and urgency while the analgesic mechanism addresses abdominal pain. In IBS-C, where transit is already sluggish, the anticholinergic slowing of motility worsens constipation symptoms and reduces tolerability. SSRIs, which accelerate transit through 5-HT4 receptor activity on enteric neurons, are better suited to IBS-C where increased propulsive activity is beneficial. The IBS subtype therefore determines which neuromodulator class is preferred.

Correct Answer

A — Methylnaltrexone or naloxegol — peripherally acting mu-opioid receptor antagonists that reverse enteric nervous system opioid effects without crossing the blood-brain barrier, preserving analgesia

Rationale

This patient has refractory opioid-induced constipation — the clinical scenario for which peripherally acting mu-opioid receptor antagonists (PAMORAs) were specifically designed. Conventional laxatives (senna, PEG) have already failed, which is expected because they do not address the receptor-mediated mechanism driving his constipation. PAMORAs block mu-opioid receptors in the enteric nervous system: methylnaltrexone's permanent quaternary ammonium charge prevents CNS penetration; naloxegol's P-glycoprotein substrate status at the blood-brain barrier limits CNS exposure to less than 1 percent of plasma levels. Both reverse enteric opioid effects and produce bowel movements within 24 to 48 hours without reducing central analgesia. Full opioid antagonists like naloxone (option B) would reverse central analgesia and are contraindicated in this setting where pain control is essential.

Correct Answer

C — Fidaxomicin 200 mg twice daily for 10 days — preferred first-line for non-severe CDI based on superior recurrence prevention compared with vancomycin

Rationale

This patient has non-severe CDI (WBC below 15,000 and creatinine below 1.5 mg/dL). Per the 2017 IDSA/SHEA guidelines, fidaxomicin 200 mg twice daily for 10 days is the preferred first-line agent for non-severe CDI because it achieves similar clinical cure rates to oral vancomycin but reduces recurrence by approximately 40 percent — a clinically meaningful difference, particularly important in this elderly patient who is at inherently elevated recurrence risk. Metronidazole (option A) has been downgraded and is no longer recommended as first-line for any CDI severity category; head-to-head trials show inferior cure rates and higher recurrence compared with vancomycin. Oral vancomycin (option B) remains acceptable when fidaxomicin is unavailable or cost-prohibitive. Fecal microbiota transplant (option D) is reserved for second or subsequent recurrences, not initial CDI.

Correct Answer

B — Alosetron may be appropriate given her severe refractory IBS-D, but requires REMS program enrollment, patient education on stopping if constipation or rectal bleeding occurs, and is approved only for women

Rationale

Alosetron is a 5-HT3 antagonist approved specifically for women with severe IBS-D that has not responded to conventional therapies — this patient meets both criteria. Prior cholecystectomy is not a contraindication to alosetron; it is the contraindication to eluxadoline (sphincter of Oddi spasm risk from mu-opioid agonism). Alosetron's risks are ischemic colitis and severe constipation, not pancreatitis. It remains under a REMS program requiring physician enrollment and mandatory patient education: patients must be instructed to stop the drug immediately if they develop constipation or rectal bleeding. Option C is incorrect because eluxadoline is absolutely contraindicated post-cholecystectomy — the wrong drug for this patient. Option D is incorrect: alosetron is not first-line and the REMS requirement was not removed; it was the condition of reintroduction.

Correct Answer

D — Linaclotide — guanylate cyclase-C agonism drives luminal chloride secretion improving transit, and luminal cGMP directly inhibits submucosal pain-sensing neurons through a mechanism distinct from laxation

Rationale

This patient's unmet need is abdominal pain that persists despite improved stool consistency — the scenario that distinguishes GCC agonists from simple laxatives. Linaclotide's GCC agonism generates intracellular cGMP, which activates CFTR channels driving luminal chloride and fluid secretion (the transit benefit). Crucially, luminal cGMP also acts directly on submucosal nociceptive afferent neurons to reduce their firing threshold and pain signal transmission — a mechanistically distinct analgesic action that does not depend on improved bowel habits. Clinical trials with linaclotide in IBS-C used abdominal pain as a co-primary endpoint and demonstrated significant pain reduction beyond what is explained by improved stool consistency alone. This dual mechanism makes GCC agonists the most appropriate pharmacological escalation when osmotic agents have improved transit but not pain in IBS-C.